Castle | $1,000,000 | (Jun 27, 2025)
Handspring Health | $12,000,000 | (Jun 27, 2025)
DejaBlue | $8,000,000 | (Jun 27, 2025)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Certify | $40,000,000 | (Jun 27, 2025)
Tacta Systems, Inc. | $7,000,000 | (Jun 27, 2025)
Antler Bio | $4,212,546 | (Jun 27, 2025)
Raphe mPhibr | $100,000,000 | (Jun 27, 2025)
DataBahn.ai | $17,000,000 | (Jun 27, 2025)
Klutch AI | $8,000,000 | (Jun 27, 2025)
Niural | $31,000,000 | (Jun 27, 2025)
Jarsy Inc | $5,000,000 | (Jun 27, 2025)
Spekter Games | $5,000,000 | (Jun 27, 2025)